PDT Partners LLC Takes $4.25 Million Position in Smith & Nephew SNATS, Inc. $SNN

PDT Partners LLC purchased a new stake in Smith & Nephew SNATS, Inc. (NYSE:SNN) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 67,780 shares of the medical equipment provider’s stock, valued at approximately $4,251,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in SNN. BlackRock Inc. bought a new stake in Smith & Nephew SNATS during the second quarter worth approximately $505,323,000. River Road Asset Management LLC lifted its stake in shares of Smith & Nephew SNATS by 13.8% in the 4th quarter. River Road Asset Management LLC now owns 3,169,644 shares of the medical equipment provider’s stock valued at $103,996,000 after purchasing an additional 384,926 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Smith & Nephew SNATS by 5.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,053,726 shares of the medical equipment provider’s stock worth $67,383,000 after purchasing an additional 100,697 shares during the period. Bank of New York Mellon Corp purchased a new position in shares of Smith & Nephew SNATS in the 2nd quarter worth approximately $89,325,000. Finally, Dimensional Fund Advisors LP increased its position in shares of Smith & Nephew SNATS by 44.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,052,747 shares of the medical equipment provider’s stock valued at $33,436,000 after purchasing an additional 324,080 shares during the last quarter. Hedge funds and other institutional investors own 25.64% of the company’s stock.

Smith & Nephew SNATS Stock Down 1.4%

NYSE:SNN opened at $29.21 on Wednesday. Smith & Nephew SNATS, Inc. has a twelve month low of $28.56 and a twelve month high of $38.79. The stock has a fifty day simple moving average of $30.28 and a 200-day simple moving average of $31.78. The company has a current ratio of 2.14, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62.

Smith & Nephew SNATS Announces Dividend

The business also recently disclosed a dividend, which will be paid on Friday, November 6th. Investors of record on Friday, October 2nd will be issued a dividend of $0.312 per share. The ex-dividend date is Friday, October 2nd. This represents a yield of 205.0%.

Analyst Ratings Changes

Several analysts recently weighed in on SNN shares. Canaccord Genuity Group decreased their price target on Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating on the stock in a report on Monday, May 11th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Smith & Nephew SNATS in a research note on Monday, May 25th. Sanford C. Bernstein set a $31.85 price objective on shares of Smith & Nephew SNATS in a research report on Monday, May 11th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Smith & Nephew SNATS in a research note on Thursday, August 6th. Finally, Kepler Capital Markets lowered shares of Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a report on Thursday, June 4th. Two investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $30.93.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.